Joint venture · GCC · Announced 23 Jul 2026

Lifera → Jamjoom Pharma

Jamjoom Pharma signed a binding agreement to take 49% of Biologics Co., a PIF-owned Lifera SPV set up to build and operate a Saudi vaccines, biologics and biosimilars plant, with a five-year shareholder funding commitment.

Parties: Lifera (Pharmaceutical Investment Company) (Saudi Arabia) → Jamjoom Pharma (Saudi Arabia)

Deal type
Joint venture
Value
See terms
Territory
Saudi Arabia
Therapeutic area
Vaccines
Assets
vaccines; biologics; biosimilars
Announced
23 Jul 2026

Our analysis

Why this matters

Jamjoom Pharmaceuticals Factory Co. disclosed on Tadawul on 23 July 2026 that, the day before, it had signed a binding share subscription agreement with Biologics Co. It also signed a shareholders' agreement with Biologics Co. and with Pharmaceutical Investment Company (Lifera), the Public Investment Fund's pharmaceutical company. Lifera set up Biologics Co. as a special purpose vehicle to build, own and operate a plant in Saudi Arabia to manufacture and commercialise vaccines, biologics and biosimilars.

Jamjoom will subscribe for 4,900 new shares at SAR 100 par, a total of SAR 490,000. After completion Lifera will hold 51% and Jamjoom 49%; Argaam's text and Maaal's headline both give 49%, though one Argaam table shows 45%. Under the shareholders' agreement, shareholders must fund Biologics Co. for five years in line with its approved business plan. Jamjoom said the wider financial impact will be clear once that plan is finalised.

The full analysis is free to read with a work email on this page.

Source: Argaam (Tadawul disclosure)

More deals involving Lifera or Jamjoom Pharma

Latest deals

All GCC deals → · All joint venture deals → · Browse all emerging-market pharma deals →